Get the Weekly Intelligence Brief — top committee picks every Sunday.

DOC vs EQR

Healthpeak Properties vs Equity Residential — AI-powered side-by-side comparison
DOC
Healthpeak Properties
64
Buy
VS
EQR
Equity Residential
63
Buy
MetricDOCEQR
AI Score 64 63
Price $20.50 $65.09
P/E Ratio 58.60× 28.18×
ROE 1.0% 10.1%
Revenue Growth YoY
Gross Margin 2.5% 46.0%
Debt / Equity 1.32× 0.81×
Dividend Yield 5.9% 4.3%
RSI (14) 31.1 33.4
Beta 0.991 0.749
Expected Upside +1.6% +0.6%

AI Committee View

Current Innellis committee reasoning for DOC versus EQR.
DOC leads by 1 points.

DOC scores 64/100 (Buy) versus EQR at 63/100 (Buy).

DOC Committee View
50% agreement
4 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading below the lower Bollinger Band -- stretched to the downside — Technical
EQR Committee View
50% agreement
4 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • 2 consecutive earnings misses -- execution concerns — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
DOC Full Analysis EQR Full Analysis